The stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a huge mover today! About 990,622 shares traded hands. Halozyme Therapeutics, Inc. (NASDAQ:HALO) has risen 37.83% since March 8, 2016 and is uptrending. It has outperformed by 28.51% the S&P500.
The move comes after 8 months negative chart setup for the $1.53 billion company. It was reported on Oct, 11 by Barchart.com. We have $10.86 PT which if reached, will make NASDAQ:HALO worth $91.80 million less.
Analysts await Halozyme Therapeutics, Inc. (NASDAQ:HALO) to report earnings on November, 14. They expect $-0.27 EPS, down 42.11% or $0.08 from last year’s $-0.19 per share. After $-0.21 actual EPS reported by Halozyme Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 28.57% negative EPS growth.
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage
Out of 5 analysts covering Halozyme Therapeutics (NASDAQ:HALO), 5 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Halozyme Therapeutics has been the topic of 7 analyst reports since August 11, 2015 according to StockzIntelligence Inc. JMP Securities maintained it with “Market Outperform” rating and $20 target price in Wednesday, March 9 report. As per Friday, September 16, the company rating was maintained by Piper Jaffray. JMP Securities maintained Halozyme Therapeutics, Inc. (NASDAQ:HALO) rating on Tuesday, August 11. JMP Securities has “Market Outperform” rating and $22 price target. The rating was initiated by Barclays Capital with “Overweight” on Tuesday, September 22. Wells Fargo initiated the shares of HALO in a report on Friday, December 4 with “Outperform” rating. Citigroup initiated Halozyme Therapeutics, Inc. (NASDAQ:HALO) on Wednesday, November 18 with “Buy” rating. Barclays Capital maintained it with “Overweight” rating and $16 target price in Wednesday, February 24 report.
According to Zacks Investment Research, “Halozyme Therapeutics, Inc. is a therapeutically driven, development stage biopharmaceutical company dedicated to developing and commercializing recombinant human enzymes for the infertility, ophthalmology, and oncology communities. The company’s broad product development portfolio, including expected near- and long-term product offerings, is based on intellectual property covering the family of human enzymes known as hyaluronidases. The company’s initial products are being developed to offer safer and purer alternatives toexisting slaughterhouse derived extracts that carry risks of pathogen contamination, immunogenicity, and toxicity. The commercialization of Halozyme’s highly versatile enzyme technology within proven markets will enable the company to positively impact the quality of medicine.”
Insitutional Activity: The institutional sentiment decreased to 1.04 in 2016 Q2. Its down 0.29, from 1.33 in 2016Q1. The ratio dropped, as 21 funds sold all Halozyme Therapeutics, Inc. shares owned while 46 reduced positions. 17 funds bought stakes while 53 increased positions. They now own 103.28 million shares or 2.86% more from 100.41 million shares in 2016Q1.
Tfs Cap Ltd Liability has 0.03% invested in the company for 16,286 shares. Doheny Asset Mgmt Ca last reported 107,900 shares in the company. Wfg Advsrs Lp holds 0% or 300 shares in its portfolio. Moreover, Aqr Management Ltd Liability has 0% invested in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 15,629 shares. Meeder Asset Mgmt holds 17,955 shares or 0.01% of its portfolio. Allianz Asset Management Ag has 0% invested in the company for 215,889 shares. Alliancebernstein Lp last reported 173,394 shares in the company. Hightower Advisors Limited Liability Corp owns 39,050 shares or 0% of their US portfolio. Cubist Systematic Strategies Ltd Liability Corp, a Connecticut-based fund reported 31,874 shares. Amer Intl Gp owns 62,768 shares or 0% of their US portfolio. Secor Advsr L P has 53,638 shares for 0.06% of their US portfolio. Teachers Advsrs reported 721,934 shares or 0.01% of all its holdings. Proshare Advsr Limited Liability Company holds 0.01% of its portfolio in Halozyme Therapeutics, Inc. (NASDAQ:HALO) for 113,149 shares. Blackrock Institutional Tru Company Na last reported 0% of its portfolio in the stock. Fmr Llc last reported 6.69 million shares in the company.
More news for Halozyme Therapeutics, Inc. (NASDAQ:HALO) were recently published by: Fool.com, which released: “Why Halozyme Therapeutics, Inc. Stock Jumped 21.2% in September” on October 10, 2016. Investorplace.com‘s article titled: “Halozyme Therapeutics, Inc. (HALO) Keeping Good Company” and published on September 30, 2016 is yet another important article.
HALO Company Profile
Halozyme Therapeutics, Inc., incorporated on August 23, 2007, is a biotechnology firm focused on developing and commercializing oncology therapies. The Firm operates in research, development and commercialization of enzymes segment. This segment also includes research and development, and bulk rHuPH20 manufacturing activities conducted under its collaborative agreements with third parties, and product sales of Hylenex recombinant. The Company’s research activities focus on human enzymes that alter the extracellular matrix and tumor microenvironment. The Company’s enzymes are used to facilitate the delivery of injected drugs and fluids. The Company’s rHuPH20 is the active ingredient in its commercially approved product, Hylenex recombinant, and it works by temporarily breaking down hyaluronan (HA), a naturally occurring complex carbohydrate that is a component of the extracellular matrix in tissues throughout the body, such as skin and cartilage. The Firm refers to the application the delivery of other drugs or fluids as its ENHANZE Technology. It licenses the ENHANZE Technology to form collaborations with biopharmaceutical companies that develop or market drugs requiring injection through the subcutaneous route of administration.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.